Raffles Medical Group » COVID-19 » COVID-19 Vaccines » Pfizer-BioNTech COVID-19 Vaccine

Pfizer-BioNTech COVID-19 Vaccine

Registration for interest in the Sinopharm vaccine is now available. Register your interest.

What you need to know about Pfizer-BioNTech vaccine

The first COVID-19 vaccine to be approved for emergency use by the World Health Organisation in December 2020, the Pfizer-BioNTech COVID-19 vaccine today is used globally in the fight against COVID-19. The Pfizer-BioNTech vaccine is also approved by Singapore’s Health Sciences Authority and is part of Singapore’s national vaccination programme.

On this page:

What’s different about the Pfizer-BioNTech vaccine?

12 years old and above

Approved for use in adolescents

Pfizer-BioNTech is one of the only COVID-19 vaccines that is approved for use in adolescents, aged 12 years and above.

uses mRNA technology

First mRNA vaccine to be developed for COVID-19

Developed by German company BioNTech in partnership with Pfizer, this vaccine is the first widely-available vaccine to use mRNA technology.

globally approved COVID-19 vaccine

Approved by 88 countries globally

The Pfizer-BioNTech vaccine is approved for use in 88 countries globally and counting.

Who is eligible for taking Pfizer-BioNTech?

Individuals aged five years and older with:

  • No history of anaphylaxis to mRna COVID-19 vaccines or its components, and
  • No high-risk allergic reactions to a previous dose of mRna COVID-19 vaccine or its components

The booster vaccine is applicable for those aged 12 years and older.

Source: /https://www.moh.gov.sg/covid-19/vaccination

What is the recommended dosage for administration?

  • The dosing regimen for the primary vaccination (two doses) is 21 days apart.
  • A booster dose is recommended to be taken five months after being vaccinated with two doses of the Pfizer-BioNTech or Moderna / Spikevax vaccines.

Source: www.vaccine.gov.sg/faq

If you are unsure of your suitability for the vaccine, please consult your doctor first.

How safe is Pfizer-BioNTech?

Efficacy rate of 95% in preventing Covid-19 symptomatic disease in adults aged 16 years and older.